Current in vitro sensitivity of the most frequent bacterial respiratory pathogens: Clinical implications;Sensibilidad in vitro actual de los patógenos respiratorios bacterianos más frecuentes: Implicaciones clínicas

Medicina Clinica

Volumn 116, Issue 14, 2001, Pages 541-549

  Oteo, J ^a   Alos J I ^a   Gomez Garces J L ^a  

^a HOSPITAL DE MÓSTOLES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC BRONCHITIS; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; OTITIS MEDIA; PNEUMONIA; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0001334880     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71898-2     Document Type: Article

References (124)

1. Resistance to penicillin and cephalosporin and mortality from severe pneumoccocal pneumonia in Barcelona, Spain
2. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumoccocal disease
3. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
4. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program
5. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
6. Multicenter surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the 1998-1999 respiratory season
7. Comparative activity of 27 antimicrobial compounds againts 698 Streptococcus pneumoniae isolates originating from 20 European University Hospitals
8. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) study
9. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
10. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
11. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989
12. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990-1996)
13. Antimicrobial resistance of Streptococcus pneumoniae in 1999-2000 in Madrid (Spain): Multicenter surveillance study
14. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
15. Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996
16. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States
17. In vitro susceptibilities of 185 penicillin-susceptible and resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxycillin, amoxycillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir
18. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
19. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci
20. Genetic and biochemical mechanisms of bacterial resistance to antimicrobial agents
21. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrollides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
22. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
23. Comparative susceptibility to penicillin and quinolones of 1358 Streptococcus pneumoniae isolates
24. Decreased susceptibility of Streptococcus pneumoniae to fluorquinolones in Canada
25. Fluorquinolone resistance in Streptococcus pneumoniae
26. Emergence of Fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
27. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States
28. Ampicillin-resistant Haemophilus influenzae type b infection
29. Ampicillin-resistant Haemophilus influenzae
30. Haemophilus influenzae type b resistant to ampicillin: A report of two cases
31. Resistancias en Haemophilus influenzae en España. Segundo estudio (1990)
32. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavunate: Results of a national multicenter surveillance study
33. Haemphilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
34. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
35. Susceptibility of Haemophilus influenzae isolated in Spain in 1999 to 17 oral antimicrobial agents. A prospective national study
36. Antomicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-1997) multicenter surveillance study
37. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterizacion of their β-lactamases
38. Distribution and resistance patterns of Haemophilys influenzae ad European cooperative study
39. The second European collaborative study on the frequency of antimicrobial resistance in Haemophiluz influenzae
40. Survey of β-lactamase-producing Haemophilus influenzae
41. Presence of ROB-1 β-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae
42. Molecular basis of non-β-lactamase-mediated resistance to β-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada
43. In vitro and in vivo anti-bacterial activity of T-2588M, a new oral cephalosporin, compared with those of other oral β-lactam antibiotics
44. Recent evaluation of antimicrobial resistance en β-hemolitic streptococci
45. Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades
46. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: Results of a Spanish multicentre study in 1998
47. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
48. Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis
49. Five days of erythromycin versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children: Pharyngitis Study Group
50. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis
51. Antibiotic susceptibility of group A streptococci: A 6-year follow-up study
52. Erythromycin resistance in streptococci
53. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy
54. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogens in Italy, 1993-1995
55. Decreased activity of erythromycin against Streptococcus pyogens in Taiwan
56. Resistance to erythromycin in group A streptococci
57. Outpatient use of erythromycin: Link to increased erythromycin resistance, in group A streptoccocci
58. Emergence of erythromycin-resistant clindamycin-susceptible Streptococcus pyogenes in Madrid, Spain
59. Erythromycin resistance of Streptococcus pyogenes in Madrid
60. Emergence of Streptococcus pyogenes strains resistant to erythromycin in Gipuzcoa, Spain
61. Survey of macrolides resistance phenotypes in Swedish clinical isolates of Streptococcus pyogenes
62. Erythromycin resistance genes in group A streptococci in Finland
63. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistance strains
64. Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin
65. Macrolide resistance in group A streptococci
66. Moraxella catarrhalis and other gran-negative cocci
67. Determination of the antimicrobial susceptibities of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis Streptococcus pneumoniae
68. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland
69. The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991
70. Resistance surveillance of Streptoccus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
71. Long-term trends in susceptibility of Moraxella catarrhalis: A population analysis
72. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in USA
73. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998
74. Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern
75. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis
76. In vitro activities of ketolides HRM 3647 and HRM 3004, levofloxacin, and other quinolone and macrolides against Neisseria spp. and Moraxella catarrhalis
77. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR106972 against Mycoplasma pneumoniae
78. In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas
79. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp
80. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas
81. Transition mutation in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae
82. Legionnaires' disease: Description of an epidemic of pneumonia
83. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracelular susceptibility testing in HL-60 cells
84. Susceptibilities of Legionella spp. to newer antimicrobials In vitro
85. In vitro activity of antibiotics against Legionella pneumophila isolates from water systems
86. In vitro activity of azithromycin against clinical isolates of Legionella species
87. Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila
88. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp
89. In vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections
90. Activity of trovofloxacin (CP-99,219) against Legionella isolates: In vitro activity intracellular accumulation and killing in macrophages, and pharmaco-kinetics and treatment of guinea pigs with L. pneumophila pneumonia
91. In vitro of levofloxacin against clinical isolates of Legionella spp., its pharmokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia
92. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies
93. Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents
94. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp
95. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: Influence of charcoal on susceptibility test results
96. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila
97. Comparison of the activity of three antibiotic regimens in severe legionaires' disease
98. Penicillin-resistant Streptococcus pneumoniae: Selection by both β-lactam and non-β-lactam antibiotics
99. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
100. Postantibiotic effect
101. Intracelular activity, potencial clinical uses of antibiotics
102. Comparison of the plasma urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects
103. Clinical efficacy of antimicrobial drugs for acute otitis media: Metaanalysis of 5,400 children from thirty-three ramdomized trials
104. In vitro, in vivo and ex vivo studies with oral beta-lactams against Streptococcus pneumoniae
105. In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media
106. Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice
107. Low dosage and long treatment duration of β-lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
108. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
109. Treatment of acute otitis media with a shortened course of antibiotics. A meta-analysis
110. Are antibiotics indicated as initial treatment for children with acute otitis media?. A meta-analysis
111. Antimicrobials for acute otitis media? A review from the International Primary Care Network
112. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain
113. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinusitis infections in children: A double-blind, placebo controlled trial
114. Diagnosis and management of group A streptococcal pharyngitis: A practice guideline
115. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the medical research council by their working party on trials of chemotherapy in early chronic bronchitis
116. Bacterial infection in chronic obstructive pulmonary disease
117. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
118. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance
119. Penicillin resistance and other predictors of mortality in pneumococcal bacteriemia in a population with high HIV seroprevalence
120. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
121. Antimicrobial chemotherapy for Legionnaire's disease: Time for a change
122. The treatment of Legionnares' disease